Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.76 |
| ▸ | MEN1 | O00255 | 5/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.76 |
| ▸ | HPGD | P15428 | 2/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | POLB | P06746 | 2/20 | 0.75 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.75 |
| ▸ | MAOA | P21397 | 3/20 | 0.73 |
| ▸ | MAOB | P27338 | 3/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5088006 | 1.00 | MAPT (0.76) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL25265052 | 0.89 | MAPT (0.80) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL30383556 | 0.89 | MAPT (0.80) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL25191007 | 0.89 | MAPT (0.80) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL25327273 | 0.89 | MAPT (0.89) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL5422585 | 0.86 | MAPT (0.80) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL5082144 | 0.86 | MAPT (1.00) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL5082149 | 0.86 | MAPT (1.00) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL5422587 | 0.86 | MAPT (0.80) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL14692628 | 0.86 | NR1H4 (0.79) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-10 | — | — | US | disclosed |
| WO-2017132135-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-03 | — | — | WO | disclosed |
| US-9085520-B2 | Composition for treating diabetes and metabolic diseases and a preparation method thereof | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2015-07-21 | — | — | US | disclosed |
| US-9085520-B2 | Composition for treating diabetes and metabolic diseases and a preparation method thereof | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2015-07-21 | — | — | US | disclosed |
| US-9085520-B2 | Composition for treating diabetes and metabolic diseases and a preparation method thereof | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2015-07-21 | — | — | US | disclosed |
| US-20140350304-A1 | COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-11-27 | — | — | US | disclosed |
| US-20140350304-A1 | COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-11-27 | — | — | US | disclosed |
| US-20140350304-A1 | COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-11-27 | — | — | US | disclosed |
| US-20140194474-A1 | COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-07-10 | — | — | US | disclosed |
| US-20140194474-A1 | COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-07-10 | — | — | US | disclosed |
| US-20130040996-A1 | COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-02-14 | — | — | US | disclosed |
| US-20130040996-A1 | COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-02-14 | — | — | US | disclosed |
| WO-2013022951-A1 | COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-02-14 | — | — | WO | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | MAPT 4566/4885SMN1; SMN2 3973/4885MEN1 4281/4885 |
| US-20130040996-A1 | COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF | CDK4, PPARD, CCND1 | MAPT 4298/4885SMN1; SMN2 4590/4885MEN1 4710/4885 |
| US-20140194474-A1 | COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF | CDK4, PPARD, CCND1 | MAPT 4298/4885SMN1; SMN2 4590/4885MEN1 4710/4885 |
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | ESRRG, GPER1, ESR2 | MAPT 4210/4885SMN1; SMN2 3164/4885MEN1 4505/4885 |
| US-20140350304-A1 | COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF | FABP1, GYS2, CYP7B1 | MAPT 4070/4885SMN1; SMN2 4559/4885MEN1 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.